James Brugarolas
Affiliations: | 1994-1998 | Biology | Massachusetts Institute of Technology, Cambridge, MA, United States |
Google:
"James Brugarolas"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Prakasam G, Mishra A, Christie A, et al. (2024) Comparative genomics incorporating translocation renal cell carcinoma mouse model reveals molecular mechanisms of tumorigenesis. The Journal of Clinical Investigation |
| Kapur P, Brugarolas J, Trpkov K. (2023) Recent Advances in Renal Tumors with TSC/mTOR Pathway Abnormalities in Patients with Tuberous Sclerosis Complex and in the Sporadic Setting. Cancers. 15 |
| Bezwada D, Brugarolas J. (2023) Reporting on FH-deficient renal cell carcinoma using circulating succinylated metabolites. The Journal of Clinical Investigation. 133 |
| Kaushik AK, Tarangelo A, Boroughs LK, et al. (2022) In vivo characterization of glutamine metabolism identifies therapeutic targets in clear cell renal cell carcinoma. Science Advances. 8: eabp8293 |
| Kapur P, Zhong H, Araj E, et al. (2022) Predicting Oncologic Outcomes in Small Renal Tumors. European Urology Oncology |
| Kapur P, Rajaram S, Brugarolas J. (2022) The expanding role of BAP1 in clear cell renal cell carcinoma. Human Pathology |
| Yao C, Zhang T, Wu T, et al. (2022) Facts and hopes for immunotherapy in renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Zhou J, Simon JM, Liao C, et al. (2022) An oncogenic JMJD6-DGAT1 axis tunes the epigenetic regulation of lipid droplet formation in clear cell renal cell carcinoma. Molecular Cell |
| Freifeld Y, Pedrosa I, Mclaughlin M, et al. (2022) Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus. Urologic Oncology |
| Hannan R, Christensen M, Hammers H, et al. (2021) Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer. European Urology Oncology |